Tearsheet

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 59%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -82%

Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Medical Cannabis Therapeutics & Clinics, Geriatric Care, Show more.

Weak multi-year price returns
2Y Excs Rtn is -132%, 3Y Excs Rtn is -165%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -246 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6279%

Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 296%

Expensive valuation multiples
P/SPrice/Sales ratio is 15x

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1172%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1173%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -497%

High stock price volatility
Vol 12M is 170%

Key risks
NAKA key risks include [1] a potential Nasdaq delisting due to its low stock price, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 59%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -82%
2 Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Medical Cannabis Therapeutics & Clinics, Geriatric Care, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -132%, 3Y Excs Rtn is -165%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -246 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6279%
5 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 296%
6 Expensive valuation multiples
P/SPrice/Sales ratio is 15x
7 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 101%
8 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1172%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1173%
9 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -497%
10 High stock price volatility
Vol 12M is 170%
11 Key risks
NAKA key risks include [1] a potential Nasdaq delisting due to its low stock price, Show more.

NAKA in ETFs

Weight = NAKA's share of each fund

ITOT0.00%
SCHA0.00%
SCHB0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 7/1/2026

Nakamoto (NAKA) stock has lost about 60% since 3/31/2026 because of the following key factors:

1. Significant Fiscal Q2 2026 Earnings Miss and Net Loss. On May 12, 2026, Nakamoto reported a substantial earnings miss for its fiscal Q2 2026, posting an Earnings Per Share (EPS) of -$15.20 against an estimated $0.40, representing a miss of 3,900%. This was compounded by a net loss of $238.8 million for fiscal Q1 2026, largely driven by a $102.5 million unrealized loss tied to Bitcoin prices and the sale of 284 BTC to cover working capital needs, contributing to negative investor sentiment.

2. Nasdaq Minimum Bid Price Non-Compliance and Reverse Stock Split. Nakamoto faced a significant threat of delisting from Nasdaq, as its stock had traded below the $1.00 minimum bid price since December 10, 2025, with a compliance deadline of June 8, 2026. To regain compliance, the company implemented a 1-for-40 reverse stock split, effective May 22, 2026. While this action mechanically raised the share price, it often signals underlying financial distress and raised concerns about potential future share dilution, given the existence of 10 billion authorized but unissued shares.

Show more
Updated on 7/1/2026

Nakamoto (NAKA) stock has lost about 60% since 3/31/2026 because of the following key factors:

1. Significant Fiscal Q2 2026 Earnings Miss and Net Loss. On May 12, 2026, Nakamoto reported a substantial earnings miss for its fiscal Q2 2026, posting an Earnings Per Share (EPS) of -$15.20 against an estimated $0.40, representing a miss of 3,900%. This was compounded by a net loss of $238.8 million for fiscal Q1 2026, largely driven by a $102.5 million unrealized loss tied to Bitcoin prices and the sale of 284 BTC to cover working capital needs, contributing to negative investor sentiment.

2. Nasdaq Minimum Bid Price Non-Compliance and Reverse Stock Split. Nakamoto faced a significant threat of delisting from Nasdaq, as its stock had traded below the $1.00 minimum bid price since December 10, 2025, with a compliance deadline of June 8, 2026. To regain compliance, the company implemented a 1-for-40 reverse stock split, effective May 22, 2026. While this action mechanically raised the share price, it often signals underlying financial distress and raised concerns about potential future share dilution, given the existence of 10 billion authorized but unissued shares.

3. Exposure to Bitcoin Price Volatility. As a "Bitcoin operating company" and a holder of a significant Bitcoin treasury (approximately 4,467 BTC after June 2026 transactions), Nakamoto's stock performance is highly sensitive to the volatile price movements of Bitcoin. The substantial unrealized loss of $102.5 million on its Bitcoin holdings significantly contributed to the reported net loss in fiscal Q1 2026, directly impacting investor confidence and stock valuation during the specified period.

4. Prior Share Dilution from Acquisitions. Concerns regarding prior share dilution from CEO David Bailey's February 2026 acquisitions of BTC Inc. and UTXO Management using company stock, a deal that reportedly doubled outstanding shares, likely continued to weigh on investor sentiment and contributed to the stock's downward trajectory leading into and during the specified period.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -57.6% change in NAKA stock from 3/31/2026 to 7/8/2026 was primarily driven by a -71.7% change in the company's P/S Multiple.
(LTM values as of)33120267082026Change
Stock Price ($)8.843.75-57.6%
Change Contribution By: 
Total Revenues ($ Mil)24115.2%
P/S Multiple53.115.0-71.7%
Shares Outstanding (Mil)1116-30.3%
Cumulative Contribution-57.6%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2026 to 7/8/2026
ReturnCorrelation
NAKA-57.6% 
Market (SPY)14.6%33.9%
Sector (XLF)11.3%5.4%

Fundamental Drivers

The -73.3% change in NAKA stock from 12/31/2025 to 7/8/2026 was primarily driven by a -67.7% change in the company's Shares Outstanding (Mil).
(LTM values as of)123120257082026Change
Stock Price ($)14.043.75-73.3%
Change Contribution By: 
Total Revenues ($ Mil)2497.9%
P/S Multiple36.015.0-58.3%
Shares Outstanding (Mil)516-67.7%
Cumulative Contribution-73.3%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 7/8/2026
ReturnCorrelation
NAKA-73.3% 
Market (SPY)9.6%36.2%
Sector (XLF)0.9%20.3%

Fundamental Drivers

The -99.3% change in NAKA stock from 6/30/2025 to 7/8/2026 was primarily driven by a -99.0% change in the company's Shares Outstanding (Mil).
(LTM values as of)63020257082026Change
Stock Price ($)553.803.75-99.3%
Change Contribution By: 
Total Revenues ($ Mil)2458.6%
P/S Multiple34.215.0-56.1%
Shares Outstanding (Mil)016-99.0%
Cumulative Contribution-99.3%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2025 to 7/8/2026
ReturnCorrelation
NAKA-99.3% 
Market (SPY)21.7%20.4%
Sector (XLF)6.2%13.6%

Fundamental Drivers

null
null

Market Drivers

6/30/2023 to 7/8/2026
ReturnCorrelation
NAKA  
Market (SPY)74.1%16.1%
Sector (XLF)70.4%10.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
NAKA Return----59%-72%-72%-97%
Peers Return66%-84%342%78%9%30%203%
S&P 500 Return27%-19%24%23%16%10%100%

Monthly Win Rates [3]
NAKA Win Rate---25%33%29% 
Peers Win Rate48%31%77%48%58%46% 
S&P 500 Win Rate75%42%67%75%67%57% 

Max Drawdowns [4]
NAKA Max Drawdown-----99%-81% 
Peers Max Drawdown-67%-85%-49%-54%-58%-43% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: MSTR, MARA, RIOT, COIN, HUT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/8/2026 (YTD)

How Low Can It Go

EventNAKAS&P 500
2025 US Tariff Shock
  % Loss-47.4%-18.8%
  % Gain to Breakeven90.1%23.1%
  Time to Breakeven55 days79 days
2024 Yen Carry Trade Unwind
  % Loss-40.7%-7.8%
  % Gain to Breakeven68.7%8.5%
  Time to Breakeven189 days18 days

Compare to MSTR, MARA, RIOT, COIN, HUT

In The Past

Nakamoto's stock fell -47.4% during the 2025 US Tariff Shock. Such a loss loss requires a 90.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventNAKAS&P 500
2025 US Tariff Shock
  % Loss-47.4%-18.8%
  % Gain to Breakeven90.1%23.1%
  Time to Breakeven55 days79 days
2024 Yen Carry Trade Unwind
  % Loss-40.7%-7.8%
  % Gain to Breakeven68.7%8.5%
  Time to Breakeven189 days18 days

Compare to MSTR, MARA, RIOT, COIN, HUT

In The Past

Nakamoto's stock fell -47.4% during the 2025 US Tariff Shock. Such a loss loss requires a 90.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Nakamoto (NAKA)

Nakamoto (symbol: NAKA), operating as KindlyMD, Inc., is a healthcare data company dedicated to holistic pain management and reducing the impact of the opioid epidemic. The company delivers direct outpatient clinical services that integrate prescription medicine with behavioral health therapies. Its core mission is to help chronic pain patients reduce their reliance on opioids by providing evidence-based, non-opioid alternatives in conjunction with behavioral and addiction therapy, developed by embedded prescriber and therapist teams.

KindlyMD's current main services include a variety of evaluation and management offerings such as chronic pain treatment, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support, and preventative care. These services are offered on a fee-for-service basis, with forecasted plans to include reimbursement from Medicare, Medicaid, and commercial insurance payers. The company also generates revenue through product retail sales.

Beyond direct patient care, KindlyMD collects valuable data on how and why patients transition to alternative treatments, aiming to become a significant source for evidence-based guidelines and treatment models in the fight against the opioid crisis. Future revenue streams are projected to expand beyond patient services and retail to include data collection and research, educational partnerships, and service affiliate agreements, serving a broader market including researchers, healthcare institutions, and payers.

AI Analysis | Feedback

1. Livongo Health for holistic pain management and opioid addiction.

2. 'One Medical' for chronic pain and opioid reduction, but with a mission to be a leading data platform for the opioid crisis.

AI Analysis | Feedback

  • Holistic Pain Management and Addiction Treatment Services: Provides integrated medical and behavioral health services aimed at reducing opioid use and treating chronic pain, addiction, and related conditions.
  • Healthcare Data Collection and Research: Gathers valuable data on patient responses to alternative treatments and addiction patterns to inform evidence-based guidelines.
  • Retail Product Sales: Sells various products, contributing to a current and forecasted revenue stream.
  • Healthcare Education Partnerships: Engages in collaborations to educate healthcare providers and the public on non-opioid treatments and addiction prevention.
  • Service Affiliate Agreements: Establishes partnerships for broader service delivery and market penetration.

AI Analysis | Feedback

KindlyMD, operating under the symbol NAKA, primarily serves individual patients directly. Based on the company's description, its major customer categories are:

  1. Chronic Pain Patients: Individuals seeking holistic, evidence-based, and non-opioid alternatives for managing chronic pain, with a focus on reducing opioid use and dependency.

  2. Patients at Risk of or Recovering from Opioid Addiction/Dependency: Individuals who are seeking to prevent or reduce addiction and dependency on opiates, including those needing recovery support services, overdose education, and trauma/addiction therapy.

  3. Individuals Seeking General Health and Wellness Services: Patients utilizing services such as functional medicine, cognitive behavioral therapy, preventative medicine, medically managed weight loss, hormone therapy, and limited urgent care services, which contribute to overall well-being beyond specific pain or addiction treatment.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

The key risks for KindlyMD (NAKA) are:

  1. Reimbursement and Regulatory Risk: KindlyMD's current and forecasted revenue streams rely heavily on patient care services reimbursed by Medicare, Medicaid, and commercial insurance payers. Therefore, changes in government healthcare policies, insurance company reimbursement rates, or stricter regulations concerning pain management, opioid alternatives, and behavioral health services could significantly impact the company's financial viability and operational model.
  2. Data Privacy, Security, and Monetization Risk: As a "healthcare data company" that plans to generate revenue from data collection and research, KindlyMD faces substantial risks related to data privacy and security. Handling sensitive health information necessitates strict compliance with regulations like HIPAA. Data breaches, non-compliance with privacy laws, or difficulties in monetizing healthcare data due to regulatory hurdles or limited market demand could lead to significant financial penalties, reputational damage, and hinder a key forecasted revenue stream.
  3. Market Adoption and Efficacy of Treatment Model Risk: KindlyMD's core mission is to reduce opioid use through an integrated model of prescriber and therapist teams employing "effective and evidence-based non-opioid alternatives." The success of the business depends on the widespread acceptance and proven efficacy of this treatment model. If their methods do not gain broad market adoption among patients and healthcare providers, or if the long-term effectiveness is not adequately demonstrated or questioned, it could negatively impact patient acquisition, partnership opportunities, and the company's ability to establish itself as a credible source for treatment guidelines.

AI Analysis | Feedback

The potential emergence of large technology companies (e.g., Google, Apple, Amazon, Microsoft) leveraging their significant data infrastructure and advanced AI/machine learning capabilities to enter the specialized market of holistic pain management and opioid addiction treatment. These entities could develop highly scalable, data-driven digital platforms offering personalized treatment programs and evidence-based guidelines, potentially surpassing KindlyMD's ability to collect and leverage proprietary data and provide integrated care on a broader scale, thus directly challenging KindlyMD's core services and its ambition to become a leading source for data and treatment models.

AI Analysis | Feedback

Nakamoto Inc. (NAKA), which operates its healthcare services through its wholly-owned subsidiary KindlyMD, Inc., addresses several significant markets within the healthcare sector in the United States.

The primary addressable markets for Nakamoto's main products and services are:

  • Addiction Treatment Market (U.S.): The U.S. addiction treatment market was valued at an estimated USD 2.44 billion in 2024 and is projected to grow to approximately USD 4.31 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 5.85% from 2025 to 2034. North America, predominantly the U.S., accounted for 37% of the global addiction treatment market in 2024.
  • Opioid Use Disorder (OUD) Treatment Market (U.S.): The U.S. market for opioid use disorder treatment is substantial, with an estimated value of USD 3.37 billion in 2025, projected to reach about USD 9.48 billion by 2035, growing at a CAGR of 10.9% from 2026 to 2035. Another report estimates the U.S. OUD market at USD 3.92 billion in 2025, with a projected increase to USD 9.27 billion by 2034 at a CAGR of 9.70% from 2026–2034.
  • Behavioral Health Services Market (U.S.): This market, encompassing services like cognitive behavioral therapy and trauma therapy, was valued at USD 66.79 billion in 2025 and is expected to exceed USD 96.80 billion by 2035, with a CAGR of 3.78% from 2026 to 2035. Other estimates place the U.S. behavioral health market at over USD 89 billion in 2024, anticipated to reach USD 165.4 billion by 2034 with a 6.4% CAGR from 2025 to 2034.
  • Chronic Pain Management Market (U.S.): The U.S. pain management market, which includes various therapies beyond just pharmaceuticals, was valued at USD 31.18 billion in 2025, projected to reach USD 42.87 billion by 2034, growing at a CAGR of 3.6% from 2026 to 2034. The broader chronic pain market in the U.S. was valued at USD 21.2 billion in 2023 and is expected to reach USD 28.9 billion by 2034.
  • Mental Health and Addiction Treatment Centers Market (U.S.): A more comprehensive market that combines mental health and addiction treatment services was estimated at USD 143.62 billion in 2024 and is projected to reach USD 408.12 billion by 2033, expanding at a CAGR of 12.3% from 2025 to 2033.
  • Healthcare Data Analytics Market (U.S.): KindlyMD's focus on data collection and research falls within the U.S. healthcare analytics market, which was estimated at USD 21.21 billion in 2024 and is projected to reach USD 67.48 billion by 2033, with a CAGR of 12.76% from 2025 to 2033. The U.S. healthcare big data analytics market was valued at USD 24.7 billion in 2025 and is projected to reach USD 62.43 billion by 2034.

AI Analysis | Feedback

The following are 3-5 expected drivers of future revenue growth for Nakamoto (NAKA) over the next 2-3 years:
  • Expansion of Patient Care Services and Payer Coverage: KindlyMD anticipates significant revenue growth through the expansion of its medical evaluation and treatment visits. This includes increasing patient volume for existing services, broadening the range of specialized outpatient clinical services such as chronic pain management, functional medicine, and various therapies, and securing wider reimbursement from Medicare, Medicaid, and commercial insurance payers, in addition to self-pay services.
  • Monetization of Data Collection and Research: A key driver will be the establishment of data collection and research as a dedicated revenue stream. KindlyMD collects valuable data on patient responses to alternative treatments and opioid reduction strategies, which it intends to leverage for commercial purposes.
  • Development of Education Partnerships: The company plans to generate revenue through education partnerships. As KindlyMD aims to become a source for evidence-based guidelines, treatment models, and education in addressing the opioid crisis, these partnerships will provide a new avenue for growth.
  • Formation of Service Affiliate Agreements: KindlyMD expects future revenue growth from establishing service affiliate agreements, indicating a strategy to partner with other entities to extend its service reach or offerings.

AI Analysis | Feedback

Share Repurchases

  • In December 2025, KindlyMD authorized a share repurchase program for up to $10 million of its outstanding common stock.
  • As of available records, no actual share repurchases have been made under the authorized program.

Share Issuance

  • In August 2025, KindlyMD announced a $5 billion at-the-market (ATM) equity offering program to be used for general corporate purposes, including its Bitcoin Treasury Strategy, working capital, acquisitions, and capital expenditures.
  • As part of its merger with Nakamoto Holdings Inc. in August 2025, KindlyMD engaged in a $710 million Private Investment in Public Equity (PIPE) offering, consisting of $510 million in common shares and pre-funded warrants, and $200 million in senior secured convertible notes.
  • In February 2026, Nakamoto Inc. issued approximately 364.8 million shares of common stock, valued at about $81.6 million, to complete the all-stock acquisitions of BTC Inc. and UTXO Management.

Inbound Investments

  • KindlyMD raised approximately $540 million from a private placement and secured $200 million in convertible notes in August 2025 as part of its merger with Nakamoto Holdings Inc., intended to fund Bitcoin purchases.

Outbound Investments

  • In August 2025, KindlyMD acquired 5,743.91 Bitcoin for approximately $679 million, bringing its total holdings to 5,764.91 BTC.
  • In February 2026, Nakamoto Inc. completed the acquisitions of BTC Inc. and UTXO Management through an all-stock transaction valued at roughly $81.6 million, expanding its Bitcoin-native enterprise portfolio.

Capital Expenditures

  • Nakamoto Inc. reported capital expenditures of $13.3K in December 2021.
  • In Q3 2024, capital expenditures by Nakamoto Inc. were $2.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

NAKAMSTRMARARIOTCOINHUTMedian
NameNakamoto Strategy MARA Riot Pla.Coinbase.Hut 8  
Mkt Price3.7593.8712.0221.09159.36106.1157.48
Mkt Cap0.131.34.67.342.211.89.6
Rev LTM44908686536,560284572
Op Inc LTM-246-40-907-389730-139-193
FCF LTM-46-22,145-1,283-1,2731,756-814-1,043
FCF 3Y Avg-17-17,902-901-1,1161,958-424-662
CFO LTM-46-51-835-6341,756-133-92
CFO 3Y Avg-17-44-650-3371,974-87-65

Growth & Margins

NAKAMSTRMARARIOTCOINHUTMedian
NameNakamoto Strategy MARA Riot Pla.Coinbase.Hut 8  
Rev Chg LTM58.6%6.8%23.1%42.4%-5.8%114.6%32.7%
Rev Chg 3Y Avg--0.6%130.6%38.6%37.1%48.6%38.6%
Rev Chg Q361.7%11.9%-18.4%3.6%-30.5%225.5%7.8%
QoQ Delta Rev Chg LTM115.2%2.8%-4.3%0.9%-8.7%20.9%1.8%
Op Inc Chg LTM-5,828.2%39.1%-62.0%-9.7%-68.3%-99.3%-65.1%
Op Inc Chg 3Y Avg--247.9%-101.0%-38.3%111.3%-368.0%-101.0%
Op Mgn LTM-6,279.0%-8.2%-104.5%-59.5%11.1%-49.0%-54.3%
Op Mgn 3Y Avg-2,165.0%-8.2%-73.0%-74.5%19.9%-36.4%-54.7%
QoQ Delta Op Mgn LTM-5,119.1%0.3%-13.8%-6.5%-9.2%-7.6%-8.4%
CFO/Rev LTM-1,171.8%-10.4%-96.2%-97.0%26.8%-46.6%-71.4%
CFO/Rev 3Y Avg-448.9%-9.3%-90.9%-62.2%31.1%-49.8%-56.0%
FCF/Rev LTM-1,173.4%-4,515.1%-147.8%-194.8%26.8%-286.4%-240.6%
FCF/Rev 3Y Avg-457.2%-3,780.6%-122.8%-243.1%30.7%-213.3%-228.2%

Valuation

NAKAMSTRMARARIOTCOINHUTMedian
NameNakamoto Strategy MARA Riot Pla.Coinbase.Hut 8  
Mkt Cap0.131.34.67.342.211.89.6
P/S15.063.95.311.26.441.513.1
P/Op Inc-0.2-775.0-5.0-18.957.8-84.6-11.9
P/EBIT-0.269.7-2.3-8.739.7-28.4-1.3
P/E-0.2-2.6-2.2-8.552.7-37.8-2.4
P/CFO-1.3-616.3-5.5-11.624.0-88.9-8.5
Total Yield-492.2%-38.8%-44.6%-11.8%1.9%-2.6%-25.3%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg--34.3%-24.8%-37.0%4.3%-18.3%-24.8%
D/E3.60.30.50.10.20.00.2
Net D/E3.00.20.40.1-0.10.00.1

Returns

NAKAMSTRMARARIOTCOINHUTMedian
NameNakamoto Strategy MARA Riot Pla.Coinbase.Hut 8  
1M Rtn-19.9%-26.2%-12.8%-17.9%-1.7%-11.3%-15.3%
3M Rtn-55.5%-26.8%26.5%30.9%-9.0%72.7%8.8%
6M Rtn-80.0%-42.0%19.2%38.1%-35.2%83.3%-8.0%
12M Rtn-99.3%-76.4%-31.4%82.3%-55.1%407.9%-43.2%
3Y Rtn-96.9%146.5%-23.3%36.2%102.4%909.6%69.3%
1M Excs Rtn-14.3%-23.4%-3.8%-15.8%3.2%-6.8%-10.6%
3M Excs Rtn-68.9%-37.2%21.1%35.5%-22.1%88.4%-0.5%
6M Excs Rtn-89.9%-51.4%5.1%34.2%-45.9%73.8%-20.4%
12M Excs Rtn-119.3%-96.4%-48.3%62.5%-75.5%380.4%-61.9%
3Y Excs Rtn-165.0%106.0%-81.4%10.3%54.6%841.5%32.4%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Healthcare operations23   
Bitcoin Operations00   
Other00   
Patient care services  442
Product retail sales  000
Service affiliate agreements  0  
Total23443


Operating Income by Segment
$ Mil20252024
Healthcare operations-7-3
Other-130
Bitcoin Operations-1770
Total-197-3


Assets by Segment
$ Mil20252024
Bitcoin Operations5080
Other assets2200
Healthcare operations24
Total7314


Price Behavior

Price Behavior
Market Price$3.75 
Market Cap ($ Bil)0.1 
First Trading Date05/31/2024 
Distance from 52W High-99.4% 
   50 Days200 Days
DMA Price$5.56$16.35
DMA Trenddowndown
Distance from DMA-32.6%-77.1%
 3M1YR
Volatility105.8%170.5%
Downside Capture635.41663.01
Upside Capture70.30-62.55
Correlation (SPY)31.4%19.8%
NAKA Betas & Captures as of 6/30/2026

 1M2M3M6M1Y3Y
Beta2.802.222.492.642.730.05
Up Beta7.932.542.452.351.98-0.35
Down Beta2.520.880.541.022.410.26
Up Capture-127%1%39%152%-36%11%
Bmk +ve Days11244067140429
Stock +ve Days515254790209
Down Capture318%378%444%273%206%111%
Bmk -ve Days10172358112321
Stock -ve Days16263777161303

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NAKA
NAKA-99.2%170.4%-2.00-
Sector ETF (XLF)5.6%14.8%0.1613.6%
Equity (SPY)21.2%12.5%1.2620.4%
Gold (GLD)21.9%27.8%0.703.9%
Commodities (DBC)25.0%18.7%1.060.6%
Real Estate (VNQ)12.7%13.9%0.620.9%
Bitcoin (BTCUSD)-41.4%42.8%-1.1328.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NAKA
NAKA-50.1%266.4%0.25-
Sector ETF (XLF)10.3%18.6%0.4310.6%
Equity (SPY)13.2%17.1%0.6016.1%
Gold (GLD)17.8%18.3%0.79-3.6%
Commodities (DBC)7.8%19.5%0.30-0.6%
Real Estate (VNQ)2.8%18.9%0.052.2%
Bitcoin (BTCUSD)12.1%53.5%0.419.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NAKA
NAKA-29.3%266.4%0.25-
Sector ETF (XLF)14.2%22.1%0.5910.6%
Equity (SPY)15.9%17.9%0.7616.1%
Gold (GLD)11.5%16.1%0.58-3.6%
Commodities (DBC)6.4%18.0%0.28-0.6%
Real Estate (VNQ)5.4%20.7%0.222.2%
Bitcoin (BTCUSD)58.0%66.2%0.989.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date6152026
Short Interest: Shares Quantity1.1 Mil
Short Interest: % Change Since 531202613.6%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest2.9 days
Basic Shares Quantity15.7 Mil
Short % of Basic Shares7.1%

Earnings Returns History

Updated 6/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/13/20268.4%-7.0%-36.4%
11/19/2025-9.6%-7.2%-23.8%
SUMMARY STATS   
# Positive100
# Negative122
Median Positive8.4%  
Median Negative-9.6%-7.1%-30.1%
Max Positive8.4%  
Max Negative-9.6%-7.2%-36.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/13/20268.4%-7.0%-36.4%
11/19/2025-9.6%-7.2%-23.8%
SUMMARY STATS   
# Positive100
# Negative122
Median Positive8.4%  
Median Negative-9.6%-7.1%-30.1%
Max Positive8.4%  
Max Negative-9.6%-7.2%-36.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/13/202610-Q
12/31/202503/30/202610-K
09/30/202511/19/202510-Q
06/30/202508/05/202510-Q
03/31/202505/08/202510-Q
12/31/202403/28/202510-K
09/30/202411/12/202410-Q
06/30/202408/14/202410-Q
03/31/202406/27/202410-Q
12/31/202305/15/2024424B4
06/30/202309/20/2023S-1
03/31/202306/20/2023DRS/A
Collapse to Preview
Report DateFiling DateFiling
03/31/202605/13/202610-Q
12/31/202503/30/202610-K
09/30/202511/19/202510-Q
06/30/202508/05/202510-Q
03/31/202505/08/202510-Q
12/31/202403/28/202510-K
09/30/202411/12/202410-Q
06/30/202408/14/202410-Q
03/31/202406/27/202410-Q
12/31/202305/15/2024424B4
06/30/202309/20/2023S-1
03/31/202306/20/2023DRS/A

Insider Activity

Updated 5/28/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Bailey, David FChief Executive OfficerDirectBuy52820265.6255,115309,51617,832,898Form
2Bailey, David FChief Executive OfficerDirectBuy52820264.84104,833507,34215,101,076Form
3Bailey, David FChief Executive OfficerDirectBuy52820265.5831,500175,77016,826,646Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Bailey, David FChief Executive OfficerDirectBuy52820265.6255,115309,51617,832,898Form
2Bailey, David FChief Executive OfficerDirectBuy52820264.84104,833507,34215,101,076Form
3Bailey, David FChief Executive OfficerDirectBuy52820265.5831,500175,77016,826,646Form
Core Cache Last Updated: 7/8/2026